Anakinra: Interleukin-1 receptor antagonist therapy for rheumatoid arthritis
Garces K
Record ID 32001000941
English, French
Authors' objectives:
To summarise the available evidence on the use of anakinra for rheumatoid arthritis (RA).
Authors' recommendations:
- Anakinra is an interleukin-1 receptor antagonist (IL-1ra), which blocks interleukin-1 (IL-1), a protein involved in the inflammation and the joint destruction associated with rheumatoid arthritis (RA).
- The manufacturer's submission for drug approval is currently under review by Health Canada and the FDA.
- In randomized controlled trials, patients with severe RA were treated with anakinra. Significant improvement was demonstrated in several clinical, radiologic and health-related quality of life measures in patients treated with anakinra versus placebo.
- Minimal adverse effects, mainly injection site reactions, were reported.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/research/index.html
Year Published:
2001
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Receptors, Interleukin-1
- Arthritis, Rheumatoid
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.